I’ll be honest: my first reaction to “mini menus for Ozempic users” was deep mistrust. I love food. Proper food. I revel in the kind of dinners where you order too much, eat it anyway, and feel absolutely zero regret. So when I heard that restaurants were shrinking their menus for people on weight-loss drugs – I was worried. Worried that the industry I love was in peril, vulnerable to sudden and rapid hollowing out.
After all: what happens to the joy of eating when whole swathes of the population start taking a drug that simply switches off your appetite? There isn’t much room in that reality for the excessively long menus, over-generous portions, and completely unnecessary cheese courses that I cherish.
But I kept reading, and kept thinking. And along the way, I changed my mind.
Because somewhere beneath the shrinking portion sizes, there’s a more interesting story. I’ve started to wonder whether Ozempic, of all things, might actually be the answer to some of the industry’s problems.
One in eight American adults has already taken Ozempic, Wegovy or a similar GLP-1 medication. Another 30–35% say they want to. The weight-loss drug market is on track to grow from $13.8 billion today to $48.8 billion by 2030. As a result, the US obesity rate is already ticking down measurably – from 39.9% in 2022 to 37% in 2025.
This matters because GLP-1 drugs are not just a celebrity diet fad or a luxury health trend reserved for the wealthy and the image-conscious. You won’t find the impact of the Atkins Diet or Intermittent Fasting in national statistics – the impact and footprint was too restricted, and ultimately too short-lived.
GLP-1 meanwhile is a genuine public health intervention at scale, one that is only gathering increasing pace as it enters the mainstream. No diet has ever cast this kind of shadow across the food industry. It’s throwing into question how a large part of the population engages with food and appetite fundamentally. The impact will be unavoidable for food manufacturers and the restaurant industry.
In China and India, where 1.1+ billion adults are overweight or have diabetes, Ozempic and Wegovy can cost between $100 and $200 per month. Analysts predict that generic prices could ultimately sink to $15/month amid fierce manufacturer competition.
So much of the food industry – whether it be restaurants, fast food, packaged goods, or snack brands – is built on a single reliable assumption: given enough temptation, most people will eat more than they planned to.
Think about it. Craving-trigger advertising. Supersized portions. Hyper-appealing flavours engineered to override willpower. The seductive waft of fresh bread through a restaurant’s ventilation system. That’s not an accident, that’s design. The upsell, the extra round, the dessert you didn’t intend to order. Anyone who has worked in hospitality knows this dynamic intimately: even when people come for the atmosphere, hunger and craving are doing silent work in the background to increase spend per head and profit margins.
GLP-1 drugs disable this at a neurological level. Users don’t resist temptation. The temptation itself disappears. The brain’s dopamine response to food anticipation, or food ‘noise’, simply fades into the background. Consequently, external cues like smell, advertising, and visual triggers lose their grip.
A Cornell University study from December 2025 found that within six months of starting the drug, household grocery spending drops 5.3%. Fast food and coffee shop spending falls 8%. Savory snacks – the category most deliberately engineered for compulsive eating – declined by 10%. That is more than a shift in preference. It is a huge category contraction.
The industry is already responding: Smaller, denser, more considered.
The food industry is already adapting at the surface level. Clinton Hall in New York has its ‘Teeny Weeny’ meal. Cuba Libre in DC launched a ‘GLP-Wonderful’ menu built with an obesity medicine specialist. Otto’s in London has its ‘Menu for One: Small Appetite’
What’s notable isn’t the smaller portions. It’s that they’re being named, marketed, and even in some cases medically consulted. Which means restaurants are starting to treat smaller appetites as a customer segment worth designing for.
It’s a trend visible outside of restaurants too. Nestlé launched Vital Pursuit – a whole frozen meal line specifically formulated for GLP-1 users. M&S followed with a nutrient-dense range in early 2026.
Smaller portions. Nutrient-dense reformulations. More deliberate menus. These are the common sense, surface-level responses. When appetites shrink, product formats follow.
But then there’s this: premium chocolate sales among GLP-1 users in the US rose by nearly 17% in 2025. Lindt, not exactly a brand associated with dietary restraint, is doing well in the age of Ozempic. Which could point to something deeper and more structurally interesting than just lower appetites leading to smaller portions.
GLP-1 users have stopped responding to cravings. That doesn’t mean they’ve stopped wanting pleasure from food. When the food noise is turned down, what remains isn’t indifference to food. Instead, we become more deliberate, more discerning, more present in what we choose to eat. When you’re no longer eating to satisfy a craving or reward yourself for a week of restraint, the question shifts from how much to what for. And the answer becomes: for pleasure, for curiosity, for meaning.
That has implications for what wins and what doesn’t.
Winners
Experiential dining formats
Formats where the process of eating is part of the appeal benefit from a customer who isn’t there just to be fed. From Korean BBQ and omakase to eatertainment like Netflix Bites in Las Vegas, experiences where the food is only half of the occasion.
Premium indulgence
If you’re eating less but want maximum pleasure from what you do eat, you’ll choose the one exceptional thing over three average things. Quality beats quantity when quantity is no longer the point.
Bite-sized form-factors
The thing worth having, in exactly the right amount of it. The format opportunity here extends beyond restaurants: single-serve, high-quality, portion-controlled products could become a real growth area for brands.
Losers
Diet and health foods
If a growing portion of the population no longer needs to white-knuckle their way through calorie restriction, what happens to the category of food built around that sacrifice? Why choose the lower-fat version that tastes worse, if you can eat a small amount of the real thing and feel completely satisfied?
Alcohol
While GLP-1’s headline usage is for those looking to lose weight, one side-effect of short-circuiting our usual appetite pathways is that we lose cravings in other areas – including for alcohol. Nearly 25% of GLP-1 users report stopping drinking alcohol altogether.
Convenience stores and fast food
The impact on family-size bags of crisps and bulk-buying food are self-evident, but GLP-1 will also shape distribution channels in general – convenience stores and fast food will suffer from lower foot traffic as their model relies on converting or creating sudden cravings.
The winners in a world of intentional eating share a few characteristics. They offer genuine quality. Not the appearance of it, but the real thing. They give people a reason to choose them that goes beyond hunger: an experience, a story, a flavour that earns its place. They think about pleasure and nutrition together rather than treating them as a trade-off. And they design for the deliberate customer – the person who is choosing, consciously, to spend a small appetite on this.
The brands and restaurants that should be paying attention are those that have relied, even partially, on the fact that customers couldn’t stop themselves. They’re the ones that needed appetite and craving to hijack the decision in the first place. On the extra round that got ordered because everyone was having fun. On the snack that got grabbed because the packaging was engineered to trigger a craving. On the portion size that said value more than quality. Those mechanisms are becoming less reliable.
Not for every food business. Nor for every kind of food. But for the principle of food – the idea that what we eat should be worth eating, that pleasure and quality and conscious choice should sit at the centre of how we feed ourselves.
GLP-1 creates a forced narrowing of focus on pleasure and nutrition together rather than treating them as a trade-off. Quality goes way up in relative value. It harms food brands that are lazy or rely on snap decisions as these mechanisms become less effective – not immediately, but the direction of travel looks clear.
For the food brands and hospitality businesses paying attention, GLP-1 looks less like a threat than a brief for the future – a signal about what the next generation of genuinely winning food experiences needs to look and feel like.
I should say at this point: I’m not an Ozempic user. I’m a committed, unapologetic overeater. My relationship with a restaurant menu is more archaeological dig than meal selection.
Bite-sized portions and smaller menus are, if I’m honest, quite useful for someone who orders everything anyway. More dishes, less commitment. The food I love isn’t going anywhere. It might just be arriving in slightly smaller, considerably better, portions.
135 W 41st St 5th Floor
New York NY 10036
+1 (212) 518-3444
Buspace
London
W10 5AP
